Skip to main content
Erschienen in: Digestive Diseases and Sciences 1/2011

01.01.2011 | Original Article

Clinicopathological Characteristics of 20 Cases of Hepatocellular Carcinoma with Bile Duct Tumor Thrombi

verfasst von: Xian-huan Yu, Lei-bo Xu, Chao Liu, Rui Zhang, Jie Wang

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Hepatocellular carcinoma (HCC) with bile duct tumor thrombi (BDTT) is a rare type of primary liver cancer, and its clinical and pathological characteristics remain to be defined.

Aims

To investigate the clinical and pathological characteristics of HCC with BDTT.

Methods

Among 676 HCC patients who underwent surgical treatment from Dec. 2002 to Dec. 2008 at the author’s hospital, HCC with BDTT was identified in 20 patients. The clinical and pathological characteristics of the 20 patients were measured or analyzed retrospectively. The integrity of the involved bile duct was examined macroscopically and microscopically, the expression of liver stem cell markers was investigated by immunohistochemistry, and the Kaplan–Meier method was adopted for evaluating survival.

Results

Among the 20 patients, the diameter of the primary tumor was less than 5 cm in 13 patients (range: 0.5–10 cm, mean 4.47 ± 0.68 cm). Most of the primary tumors lacked an intact tumor capsule (15/20, 75%), had simultaneous blood vessel invasion (12/20, 60%), and were poorly differentiated (13/20, 65%). There was no evidence of bile duct wall infiltration by the tumor cells macroscopically or microscopically. The positive rate of the liver stem cell markers c-kit, CD90, CD133, and EpCAM was 90, 90, 85 and 85%, respectively. Postoperative overall survival rates at 1, 2, and 3 years were 73.1, 41.1, and 20.6%, respectively. The log-rank test showed that the overall survival rates were significantly worse for HCC patients with BDTT than for HCC patients without BDTT (P = 0.016).

Conclusions

HCC with BDTT has aggressive characteristics and the long-term prognosis is extremely dismal.
Literatur
1.
Zurück zum Zitat El-Serag HB, Rudolph L. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576.CrossRefPubMed El-Serag HB, Rudolph L. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576.CrossRefPubMed
2.
3.
Zurück zum Zitat Kojiro M, Kawabata K, Kawano Y, et al. Hepatocellular-carcinoma presenting as intra-bile duct tumor-growth—a clinicopathologic study of 24 cases. Cancer. 1982;49:2144–2147.CrossRefPubMed Kojiro M, Kawabata K, Kawano Y, et al. Hepatocellular-carcinoma presenting as intra-bile duct tumor-growth—a clinicopathologic study of 24 cases. Cancer. 1982;49:2144–2147.CrossRefPubMed
4.
Zurück zum Zitat Qin LX, Tang ZY. Hepatocellular carcinoma with obstructive jaundice: diagnosis, treatment and prognosis. World J Gastroenterol. 2003;9:385–391.PubMed Qin LX, Tang ZY. Hepatocellular carcinoma with obstructive jaundice: diagnosis, treatment and prognosis. World J Gastroenterol. 2003;9:385–391.PubMed
5.
Zurück zum Zitat Liu Q, Chen J, Li H, et al. Hepatocellular carcinoma with bile duct tumor thrombi: Correlation of magnetic resonance imaging features to histopathologic manifestations. Eur J Radiol. 2009. Liu Q, Chen J, Li H, et al. Hepatocellular carcinoma with bile duct tumor thrombi: Correlation of magnetic resonance imaging features to histopathologic manifestations. Eur J Radiol. 2009.
6.
Zurück zum Zitat Shiomi M, Kamiya J, Nagino M, et al. Hepatocellular carcinoma with biliary tumor thrombi: Aggressive operative approach after appropriate preoperative management. Surgery. 2001;129:692–698.CrossRefPubMed Shiomi M, Kamiya J, Nagino M, et al. Hepatocellular carcinoma with biliary tumor thrombi: Aggressive operative approach after appropriate preoperative management. Surgery. 2001;129:692–698.CrossRefPubMed
7.
Zurück zum Zitat Peng SY, Wang JW, Liu YB, et al. Surgical intervention for obstructive jaundice due to biliary tumor thrombus in hepatocellular carcinoma. World J Surg. 2004;28:43–46.CrossRefPubMed Peng SY, Wang JW, Liu YB, et al. Surgical intervention for obstructive jaundice due to biliary tumor thrombus in hepatocellular carcinoma. World J Surg. 2004;28:43–46.CrossRefPubMed
8.
Zurück zum Zitat Peng B-G, Liang L-J, Li S-Q, et al. Surgical treatment of hepatocellular carcinoma with bile duct tumor thrombi. World J Gastroenterol. 2005;11:3966–3969.PubMed Peng B-G, Liang L-J, Li S-Q, et al. Surgical treatment of hepatocellular carcinoma with bile duct tumor thrombi. World J Gastroenterol. 2005;11:3966–3969.PubMed
9.
Zurück zum Zitat Qin L-X, Ma Z-C, Wu Z-Q, et al. Diagnosis and surgical treatments of hepatocellular carcinoma with tumor thrombosis in bile duct: Experience of 34 patients. World J Gastroenterol. 2004;10:1397–1401.PubMed Qin L-X, Ma Z-C, Wu Z-Q, et al. Diagnosis and surgical treatments of hepatocellular carcinoma with tumor thrombosis in bile duct: Experience of 34 patients. World J Gastroenterol. 2004;10:1397–1401.PubMed
10.
Zurück zum Zitat American Joint Committee on Cancer. AJCC cancer staging manual. 6th ed. New York: Springer; 2002:145–149. American Joint Committee on Cancer. AJCC cancer staging manual. 6th ed. New York: Springer; 2002:145–149.
11.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. Ca-a Cancer J Clin. 2005;55:74–108.CrossRef Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. Ca-a Cancer J Clin. 2005;55:74–108.CrossRef
12.
Zurück zum Zitat Shirabe K, Kajiyama K, Harimoto N. Prognosis of hepatocellular carcinoma accompanied by microscopic portal vein invasion. World J Gastroenterol. 2009;15:2632–2637.CrossRefPubMed Shirabe K, Kajiyama K, Harimoto N. Prognosis of hepatocellular carcinoma accompanied by microscopic portal vein invasion. World J Gastroenterol. 2009;15:2632–2637.CrossRefPubMed
13.
Zurück zum Zitat Mallory TB, Castleman B, Parris EE. Case records of the Massachusetts General Hospital. N Eng J Med. 1947;237:673–676.CrossRef Mallory TB, Castleman B, Parris EE. Case records of the Massachusetts General Hospital. N Eng J Med. 1947;237:673–676.CrossRef
14.
Zurück zum Zitat Lin TY, Chen KM, Chen YR. Icteric type hepatoma. Med Chir Dig. 1975;4:267–270.PubMed Lin TY, Chen KM, Chen YR. Icteric type hepatoma. Med Chir Dig. 1975;4:267–270.PubMed
15.
Zurück zum Zitat Tseng JH, Hung CF, Ng KK. Icteric-type hepatoma: Magnetic resonance imaging and magnetic resonance cholangiographic features. Abdom Imaging. 2001;26:171–177.CrossRefPubMed Tseng JH, Hung CF, Ng KK. Icteric-type hepatoma: Magnetic resonance imaging and magnetic resonance cholangiographic features. Abdom Imaging. 2001;26:171–177.CrossRefPubMed
16.
Zurück zum Zitat Buckmaster MJ, Schwartz RW, Carnahan GE, Strodel WE. Hepatocellular-carcinoma embolus to the common hepatic duct with no detectable primary hepatic tumor. Am Surg. 1994;60:699–702.PubMed Buckmaster MJ, Schwartz RW, Carnahan GE, Strodel WE. Hepatocellular-carcinoma embolus to the common hepatic duct with no detectable primary hepatic tumor. Am Surg. 1994;60:699–702.PubMed
17.
Zurück zum Zitat Yeh CN, Jan YY, Lee WC, Chen MF. Hepatic resection for hepatocellular carcinoma with obstructive jaundice due to biliary tumor thrombi. World J Surg. 2004;28:471–474.CrossRefPubMed Yeh CN, Jan YY, Lee WC, Chen MF. Hepatic resection for hepatocellular carcinoma with obstructive jaundice due to biliary tumor thrombi. World J Surg. 2004;28:471–474.CrossRefPubMed
18.
Zurück zum Zitat Huang GT, Sheu JC, Lee HS, et al. Icteric type hepatocellular carcinoma: Revisited 20 years later. J Gastroenterol. 1998;33:53–56.CrossRefPubMed Huang GT, Sheu JC, Lee HS, et al. Icteric type hepatocellular carcinoma: Revisited 20 years later. J Gastroenterol. 1998;33:53–56.CrossRefPubMed
19.
Zurück zum Zitat Satoh S, Ikai I, Honda G, et al. Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombi. Surgery. 2000;128:779–783.CrossRefPubMed Satoh S, Ikai I, Honda G, et al. Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombi. Surgery. 2000;128:779–783.CrossRefPubMed
20.
Zurück zum Zitat Huang JF, Wang LY, Lin ZY, et al. Incidence and clinical outcome of icteric type hepatocellular carcinoma. J Gastroenterol Hepatol. 2002;17:190–195.CrossRefPubMed Huang JF, Wang LY, Lin ZY, et al. Incidence and clinical outcome of icteric type hepatocellular carcinoma. J Gastroenterol Hepatol. 2002;17:190–195.CrossRefPubMed
21.
Zurück zum Zitat Edmondson HA, Steiner PE. Primary carcinoma of the liver—a study of 100 cases among 48, 900 necropsies. Cancer. 1954;7:462–503.CrossRefPubMed Edmondson HA, Steiner PE. Primary carcinoma of the liver—a study of 100 cases among 48, 900 necropsies. Cancer. 1954;7:462–503.CrossRefPubMed
22.
Zurück zum Zitat Narita R, Oto T, Mimura Y, et al. Biliary obstruction caused by intrabiliary transplantation from hepatocellular carcinoma. J Gastroenterol. 2002;37:55–58.CrossRefPubMed Narita R, Oto T, Mimura Y, et al. Biliary obstruction caused by intrabiliary transplantation from hepatocellular carcinoma. J Gastroenterol. 2002;37:55–58.CrossRefPubMed
23.
Zurück zum Zitat Ikenaga N, Chijiiwa K, Otani K, et al. Clinicopathologic characteristics of hepatocellular carcinoma with bile duct invasion. J Gastrointest Surg. 2009;13:492–497.CrossRefPubMed Ikenaga N, Chijiiwa K, Otani K, et al. Clinicopathologic characteristics of hepatocellular carcinoma with bile duct invasion. J Gastrointest Surg. 2009;13:492–497.CrossRefPubMed
24.
Zurück zum Zitat Sell S. Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology. 2001;33:738–750.CrossRefPubMed Sell S. Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology. 2001;33:738–750.CrossRefPubMed
25.
Zurück zum Zitat Yamashita T, Forgues M, Wang W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008;68:1451–1461.CrossRefPubMed Yamashita T, Forgues M, Wang W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008;68:1451–1461.CrossRefPubMed
26.
Zurück zum Zitat Papoulas M, Theocharis S. Primary liver tumors: Origin and target therapy. Expert Opin Ther Targets. 2009;13:957–965.CrossRefPubMed Papoulas M, Theocharis S. Primary liver tumors: Origin and target therapy. Expert Opin Ther Targets. 2009;13:957–965.CrossRefPubMed
27.
Zurück zum Zitat Liu C, Schreiter T, Dirsch O, et al. Presence of markers for liver progenitor cells in human-derived intrahepatic biliary epithelial cells. Liver Int. 2004;24:669–678.CrossRefPubMed Liu C, Schreiter T, Dirsch O, et al. Presence of markers for liver progenitor cells in human-derived intrahepatic biliary epithelial cells. Liver Int. 2004;24:669–678.CrossRefPubMed
28.
Zurück zum Zitat Mishra L, Banker T, Banker T, et al. Liver stem cells and hepatocellular carcinoma. Hepatology. 2009;49:318–329.CrossRefPubMed Mishra L, Banker T, Banker T, et al. Liver stem cells and hepatocellular carcinoma. Hepatology. 2009;49:318–329.CrossRefPubMed
Metadaten
Titel
Clinicopathological Characteristics of 20 Cases of Hepatocellular Carcinoma with Bile Duct Tumor Thrombi
verfasst von
Xian-huan Yu
Lei-bo Xu
Chao Liu
Rui Zhang
Jie Wang
Publikationsdatum
01.01.2011
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 1/2011
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1256-8

Weitere Artikel der Ausgabe 1/2011

Digestive Diseases and Sciences 1/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.